Vireo Growth (VREOF) Cost of Revenue (2020 - 2026)
Vireo Growth (VREOF) reported Cost of Revenue of $46.9 million for Q1 2026, up 287.6% on a YoY basis from $12.1 million in Q1 2025, and down 1.53% sequentially from $47.6 million in Q4 2025.
Vireo Growth (VREOF) Cost of Revenue (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Cost of Revenue data on file, last reported at $46.9 million in Q1 2026.
- For the quarter ending Q1 2026, Cost of Revenue rose 287.6% year-over-year to $46.9 million; the trailing twelve-month figure through Mar 2026 stood at $176.4 million (up 608.58% YoY), and the FY2025 full-year result was $141.7 million, up 191.43% from the prior year.
- Cost of Revenue declined to $46.9 million in Q1 2026, from $47.6 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $54.3 million in Q3 2025 to a low of $161782.0 in Q3 2023.
- A 5-year average of $12.5 million and a median of $240322.0 in 2022 frame the typical range for Cost of Revenue.
- Across the five-year window, Cost of Revenue plunged 99.21% in 2022 and jumped 22519.81% in 2025, its largest moves.
- Tracing VREOF's Cost of Revenue over 5 years: stood at $240322.0 in 2022, then dropped by 25.93% to $178017.0 in 2023, then surged by 6849.53% to $12.4 million in 2024, then soared by 284.99% to $47.6 million in 2025, then slipped by 1.53% to $46.9 million in 2026.
- Business Quant data shows VREOF's Cost of Revenue at $46.9 million in Q1 2026, $47.6 million in Q4 2025, and $54.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 2.01 Bn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 641.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 2.59 Bn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 133.40 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | 2.36 Bn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 13.80 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 586.00 Mn |
| 10 | Vireo Growth | 10.53 Bn | 10.38 Bn | 59.30 Mn | 46.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.90 Mn |
| Mar 31, 2026 | 46.90 Mn |
| Dec 31, 2025 | 47.63 Mn |
| Dec 31, 2025 | 47.63 Mn |
| Sep 30, 2025 | 54.27 Mn |
| Sep 30, 2025 | 54.27 Mn |
| Jun 30, 2025 | 27.65 Mn |
| Jun 30, 2025 | 27.65 Mn |
| Mar 31, 2025 | 12.10 Mn |
| Mar 31, 2025 | 12.10 Mn |
| Dec 31, 2024 | 12.37 Mn |
| Dec 31, 2024 | 12.37 Mn |
| Sep 30, 2024 | 239,932.00 |
| Sep 30, 2024 | 239,932.00 |
| Jun 30, 2024 | 189,946.00 |
| Jun 30, 2024 | 189,946.00 |
| Mar 31, 2024 | 222,014.00 |
| Mar 31, 2024 | 222,014.00 |
| Dec 31, 2023 | 178,017.00 |
| Dec 31, 2023 | 178,017.00 |